Advertisement

Pharmacy

Home Pharmacy
A $3.4 million grant to help a non-profit company develop a less expensive opioid overdose antidote was announced by Purdue Pharma

Opioid Maker to Pay for Overdose Antidote Development

Grant is being given to Harm Reduction Therapeutics to develop low-cost, OTC naloxone nasal spray
Three U.S. health care foundations and seven hospital groups have formed a generic drug company to combat high prices and chronic shortages of medicines.

Hospital Groups Launch Own Generic Drug Company

The company, Civica Rx, will start with 14 widely used hospital drugs
Heart transplants using drug-intoxicated donors have significantly increased

Increase Observed in Hearts From Drug-Intoxicated Donors

However, use of drug-intoxicated donor hearts does not adversely affect post-transplant survival
Published trials have larger treatment effects than unpublished trials

Publication Characteristics Tied to Treatment Effects

Larger tx effects for published versus unpublished trials; larger effects in non-English publications
High-quality health care needs to be provided to lesbian

Better Training Needed to Boost LGBTQ Patient Health Care

Issues raised at AMA discussion include knowledge gaps for transgender women, screening guidelines
Emergency department providers need evidence-based strategies to identify and manage patients with opioid use disorder

ED Plays Critical Role in Caring for Patients With Opioid Use Disorder

Review provides evidence-based strategies for identifying, managing, transitioning care
The total excess mortality attributed to Hurricane Maria is estimated at 2

~3,000 Excess Deaths Estimated Due to Hurricane Maria

Reported death counts limited by physician lack of awareness of death certification process
Fostamatinib produces clinically meaningful responses in adults with immune thrombocytopenia

Fostamatinib Seems Effective for Immune Thrombocytopenia

Overall response of platelet count ≥50,000/μL seen in 43 percent of patients
Recommendations have been developed by the World Health Organization for treatment intensification in type 2 diabetes. The recommendations were published online Sept. 4 in the Annals of Internal Medicine.

WHO Issues Recommendations for Tx Intensification in T2DM

Also, recommendations for type of insulin for type 1 and type 2 diabetes in low-resource settings
Under Medicare Part D

Out-of-Pocket Costs Similar for Infliximab, Infliximab-Dyyb

Mean total costs per eight-week prescription and annually modestly lower for infliximab biosimilar